potassium voltage-gated channel subfamily C member 2Genealiases: DEE103 · KV3.2
Q-omics provides the consensus-scored KCNC2 profile across patient tissues and cancer cell-line models. KCNC2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, KCNC2 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, KCNC2 RNA expression shows 13,637 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THCA, HNSC, and GBM as cancer lineages where KCNC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNC2 survival associations across molecular data types. KCNC2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNC2 RNA expression–survival associations across cancer types. High KCNC2 expression shows unfavorable associations in THCA, ACC, COAD, STAD and UVM, but favorable associations in LGG. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for KCNC2 RNA expression.
This table summarizes KCNC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNC2 shows lower tumor expression in HNSC and COAD and higher tumor expression in LUAD, LUSC, KIRC and LIHC. The HNSC box plot shows higher KCNC2 RNA expression in normal versus tumor tissue (log2 FC = −0.071, t-test p < 0.001).
This table shows molecular features associated with KCNC2 in patient tissues and cancer cell lines. In patient samples, KCNC2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
